Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
LabCorp operates one of the largest clinical laboratory networks in the U.S. with approximately 2,000 patient service centers and 36 primary laboratories, processing over 500,000 specimens daily. The company combines diagnostic testing services (routine blood work, esoteric testing, drug development support) with a drug development business serving biopharma clients globally. Stock performance is driven by test volume trends, reimbursement rates from Medicare/commercial payers, and drug development contract wins.
LabCorp generates revenue through fee-per-test reimbursement from insurers (Medicare, Medicaid, commercial payers) and direct contracts with hospitals/physicians for diagnostic services. Pricing power is moderate due to scale advantages and specialized esoteric testing capabilities (oncology, genetics, women's health) that command premium rates. Drug development revenue comes from multi-year contracts with biopharma companies for clinical trial support, with margins improving as trials progress. The business benefits from high fixed-cost leverage: existing laboratory infrastructure and IT systems can process incremental volume at low marginal cost, driving operating margin expansion when volumes grow. Competitive moats include national network density, proprietary test menu breadth (over 5,000 tests), and long-term payer/hospital relationships.
Diagnostic test volume trends (routine vs. esoteric mix, physician office visits, hospital admissions)
Medicare reimbursement rate changes via PAMA (Protecting Access to Medicare Act) and CLFS (Clinical Laboratory Fee Schedule)
Drug development segment bookings and backlog growth (reflects biopharma R&D spending trends)
Margin expansion initiatives (lab consolidation, automation, Dx/DD synergies)
Capital deployment (M&A in specialty diagnostics, share repurchases given 4.7% FCF yield)
PAMA reimbursement cuts: Medicare rate reductions of 10-15% implemented 2018-2020, with ongoing risk of further cuts reducing 30% of diagnostic revenue
Vertical integration by UnitedHealth/CVS/Walgreens building captive lab capabilities, disintermediating independent labs from patient access
Technology disruption from point-of-care testing, at-home diagnostics, and liquid biopsy competitors (Exact Sciences, Guardant Health) in oncology
Quest Diagnostics duopoly competition on price and hospital/health system exclusive contracts
Hospital outreach lab programs recapturing testing volume in-house, particularly for routine testing
Drug development competition from IQVIA, Syneos, PPD (now Thermo Fisher) for clinical trial services contracts
Moderate leverage at 2.5x Net Debt/EBITDA requires $1.6B annual operating cash flow to service debt and fund $500M capex
Pension obligations and lease commitments from extensive physical laboratory footprint create fixed cost burden
moderate - Diagnostic testing shows defensive characteristics (routine testing continues in downturns) but elective procedures and employer wellness programs are economically sensitive. Drug development revenue is tied to biopharma R&D budgets which can be cut during biotech funding droughts or economic stress. Overall, 60-70% of revenue is non-discretionary healthcare spending.
Rising rates have modest negative impact through higher debt service costs on $5.5B net debt (0.75x D/E). More significantly, higher rates pressure biotech funding availability, reducing clinical trial starts and drug development demand. Rate increases also compress valuation multiples for healthcare services stocks trading at 14.6x EV/EBITDA.
Minimal direct credit exposure. Revenue collection risk is low given payer mix is predominantly government (Medicare/Medicaid ~30%) and large commercial insurers. Bad debt historically 2-3% of revenue. No lending operations.
value - Stock trades at 1.7x P/S and 14.6x EV/EBITDA, below historical averages, attracting value investors focused on FCF generation (4.7% yield), margin expansion potential, and defensive healthcare exposure. Recent 85% EPS growth and improving fundamentals post-COVID also attract GARP (growth at reasonable price) investors.
moderate - Beta approximately 0.9-1.0. Healthcare services stocks exhibit lower volatility than broader market but face event risk from reimbursement policy changes and quarterly volume fluctuations. Stock has demonstrated 15.4% 1-year return with moderate drawdowns.
